Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Marcos Gómez-Revuelta, José María Pelayo-Terán, María Juncal-Ruiz, Javier Vázquez-Bourgon, Paula Suárez-Pinilla, Rodrigo Romero-Jiménez, Esther Setién Suero, Rosa Ayesa-Arriola, Benedicto Crespo-Facorro, Marcos Gómez-Revuelta, José María Pelayo-Terán, María Juncal-Ruiz, Javier Vázquez-Bourgon, Paula Suárez-Pinilla, Rodrigo Romero-Jiménez, Esther Setién Suero, Rosa Ayesa-Arriola, Benedicto Crespo-Facorro

Abstract

Background: Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up.

Method: From February 2001 to January 2011, 2 phases of a prospective, randomized, open-label study were undertaken. A total of 376 first-episode drug-naïve patients were randomly assigned to olanzapine (n = 55), risperidone (n = 63), haloperidol (n = 56), aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy.

Results: The overall dropout rate at 3 years reached 20.75%. Treatment discontinuation rates were significantly different among treatment groups (olanzapine = 69.09, risperidone = 71.43, aripiprazole = 73.08%, ziprasidone = 79.03%, haloperidol = 89.28%, and quetiapine = 95.53%) (χ2 = 79.86; P = .000). Statistically significant differences in terms of lack of efficacy, adherence, and tolerability were observed among treatment groups along the 3-year follow-up, determining significant differences in time to all-cause discontinuation (log-rank = 92.240; P = .000). Significant differences between treatments were found in the categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms, and amenorrhea.

Conclusions: Olanzapine, risperidone, and aripiprazole presented advantages for the first-line treatment of first episode of psychosis in terms of effectiveness. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.ClinicalTrials.gov Identifier: NCT02526030 https://ichgcp.net/clinical-trials-registry/NCT02526030.

Keywords: antipsychotics; first-episode-psychosis; schizophrenia.

© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
Consort flow chart.
Figure 2.
Figure 2.
Kaplan-Meyer survival graph: any cause discontinuation.

References

    1. Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry 163(Suppl 22): 39–44.
    1. Andreasen N. (1984) The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: Univ Iowa.
    1. Andreasen NC. (1989) Scale for the assessment of negative symptoms (SANS). Br J Psychiatry 155:53–58.
    1. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S (2013) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev Advance online publication. .
    1. Barnes TR. (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.
    1. Correll CU, De Hert M (2013) Antipsychotics for acute schizophrenia: making choices. Lancet 382:919–920.
    1. Correll CU, Rubio JM, Kane JM (2018) What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17:149–160.
    1. Crespo-Facorro B, Pérez-Iglesias R, Mata I, Caseiro O, Martínez-Garcia O, Pardo G, Ramirez-Bonilla M, Pelayo-Terán JM, Vázquez-Barquero JL (2011) Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res 45:763–769.
    1. Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Ortiz V, Pelayo-Terán JM, Valdizan E, Vazquez-Barquero JL (2012) Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) 219:225–233.
    1. Crespo-Facorro B, de la Foz VO, Mata I, Ayesa-Arriola R, Suarez-Pinilla P, Valdizan EM, Martinez-Garcia O, Pérez-Iglesias R (2014) Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology (Berl) 231:357–366.
    1. Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J (2016) Current data on and clinical insights into the treatment of first episode nonaffective psychosis: a comprehensive review. Neurol Ther 5:105–130.
    1. Davy V, Correll CU, Britta G, Michel P, Marc DH, Ward PB, Simon R, Fiona G, John L, Brendon S (2016) Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis. World Psychiatry 15:166–174.
    1. Emsley R, Chiliza B, Asmal L, Harvey BH (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13:50 Advance online publication. .
    1. First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders research version, patient edition with psychotic screen (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
    1. Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Ortiz-García de la Foz V, Vázquez-Bourgon J, González-Pinto A, Crespo-Facorro B (2018) Long-term antipsychotic effectiveness in first episode of psychosis: a 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol 21:1090–1101. Advance online publication. .
    1. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology: revised. Rockville: National Institute of Mental Health.
    1. Jann MW, Penzak SR (2018) Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs 32:603.
    1. Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10:26.
    1. Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B (2017) Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 234:2563–2570.
    1. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE (2008a) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097.
    1. Kahn RS, Wolfgang Fleischhacker W, Boter H, Davidson M, Vergouwe Y, M Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE (2008b) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097. [DOUBLE REFERENCE (a and b)]
    1. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192–213.
    1. Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry 18:208–224.
    1. Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K (2013) Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 33:675–681.
    1. Lee SY, Park MH, Patkar AA, Pae CU (2011) A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 35:490–496.
    1. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163.
    1. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962.
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223.
    1. Lindström L, Lindström E, Nilsson M, Höistad M(2017) Maintenance therapy with second generation antipsychotics for bipolar disorder–A systematic review and meta-analysis. J Affect Disord 213:138–150.
    1. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K(1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatr Scand 76:1–100.
    1. Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM, Crespo-Facorro B (2016) Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 77:492–500.
    1. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050–1060.
    1. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812.
    1. Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, González-Blanch C, Martínez-García O, Pardo-García G, Rodríguez-Sánchez JM, Roiz-Santiáñez R, Tordesillas-Gutiérrez D, Mata I, Vázquez-Barquero JL, Crespo-Facorro B (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the clinical programme on early phases of psychosis. Early Interv Psychiatry 2:178–187.
    1. Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, Martínez-García O, Tabarés-Seisdedos R, Crespo-Facorro B, Ayesa-Arriola R (2017) Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci 267:315–323.
    1. Pelayo-Terán JM, Gajardo-Galán V, Gómez-Revuelta M, Ortiz-García de la Foz V, Ayesa-Arriola R, Tabarés-Seisdedos R, Crespo-Facorro B (2018) Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. Eur Psychiatry 52:29–37.
    1. Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617–629.
    1. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19.
    1. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192:406–411.
    1. Smith RC, Leucht S, Davis JM (2019) Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 236:545–559.
    1. Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, Agid O (2019) Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 44:1036–1042.
    1. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H (2017) Real-world effectiveness of antipsychotic treatments in a nationwide Cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74:686–693.
    1. Vanasse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, Grignon S, Fleury MJ, Lesage A, Demers MF, Roy MA, Carrier JD, Delorme A (2016) Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand 134:374–384.
    1. Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-García de la Foz V, Suárez Pinilla P, Díaz Martínez Á, Crespo-Facorro B (2018) Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology (Berl) 235:245–255.
    1. Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G(2017) The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry 16:47.
    1. Woods SW. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj